Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SBRT sequential apatinib for advanced liver cancer
ChiCTR2100049080Phase 4Recruiting
- Sponsor
- Sichuan Provincial People's Hospital
- Start
- Jul 2021
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Rivoceranib in liver cancer and hepatocellular carcinoma (HCC), sponsored by Sichuan Provincial People's Hospital. Primary endpoints: time to disease progression and overall survival. Started Jul 2021; status: recruiting.
02
Drugs
Rivoceranib
03
Conditions
liver cancerhepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2100049080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100049080.